315
Views
11
CrossRef citations to date
0
Altmetric
Reviews

Chemical radiosensitizers: the Journal history

ORCID Icon
Pages 940-944 | Received 14 Oct 2018, Accepted 04 Jan 2019, Published online: 31 Jan 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Andrea L. DiCarlo, David R. Cassatt, Carmen I. Rios, Merriline M. Satyamitra, Yuji Zhang, Trevor G. Golden & Lanyn P. Taliaferro. (2023) Making connections: the scientific impact and mentoring legacy of Dr. John E. Moulder. International Journal of Radiation Biology 99:7, pages 1009-1015.
Read now
Bayanika Manunu, Antonio M. Serafin & John M. Akudugu. (2023) BAG1, MGMT, FOXO1, and DNAJA1 as potential drug targets for radiosensitizing cancer cell lines. International Journal of Radiation Biology 99:2, pages 292-307.
Read now
Yuechen Zhao, Yanqing Li, Ruifeng Zhang, Feng Wang, Tiejun Wang & Yan Jiao. (2020) The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy. OncoTargets and Therapy 13, pages 5429-5441.
Read now
Noor Nabilah Talik Sisin, Khairunisak Abdul Razak, Safri Zainal Abidin, Nor Fazila Che Mat, Reduan Abdullah, Raizulnasuha Ab Rashid, Muhammad Afiq Khairil Anuar & Wan Nordiana Rahman. (2020) Synergetic Influence of Bismuth Oxide Nanoparticles, Cisplatin and Baicalein-Rich Fraction on Reactive Oxygen Species Generation and Radiosensitization Effects for Clinical Radiotherapy Beams. International Journal of Nanomedicine 15, pages 7805-7823.
Read now
Nobuyuki Hamada, Carmel E. Mothersill & George Iliakis. (2019) Preface to the IJRB 60th anniversary special issue “back to our future”. International Journal of Radiation Biology 95:7, pages 799-801.
Read now

Articles from other publishers (6)

Noor Nabilah Talik Sisin & Wan Nordiana Rahman. (2023) Potentials of Bismuth-Based Nanoparticles and Baicalein Natural Compounds as Radiosensitizers in Cancer Radiotherapy: a Review. BioNanoScience 13:1, pages 300-321.
Crossref
Jinfeng Lin, Mingming Yin, Xiaoming Liu, Fanling Meng & Liang Luo. (2022) Nanomaterials Based on Functional Polymers for Sensitizing Cancer Radiotherapy. Macromolecular Rapid Communications 43:18.
Crossref
Noor Nabilah Talik Sisin, Hiroaki Akasaka, Ryohei Sasaki, Takahiro Tominaga, Hayato Miura, Masashi Nishi, Moshi Geso, Nor Fazila Che Mat, Khairunisak Abdul Razak & Wan Nordiana Rahman. (2022) Effects of Bismuth Oxide Nanoparticles, Cisplatin and Baicalein-rich Fraction on ROS Generation in Proton Beam irradiated Human Colon Carcinoma Cells. Polish Journal of Medical Physics and Engineering 28:1, pages 30-36.
Crossref
Gautham Ramesh, Shubhankar Das & Satish Rao Bola Sadashiva. (2020) Berberine, a natural alkaloid sensitizes human hepatocarcinoma to ionizing radiation by blocking autophagy and cell cycle arrest resulting in senescence. Journal of Pharmacy and Pharmacology 72:12, pages 1893-1908.
Crossref
Peter C. Ford & Katrina M. Miranda. (2020) The solution chemistry of nitric oxide and other reactive nitrogen species. Nitric Oxide 103, pages 31-46.
Crossref
Kirill V. Morozov, Maria A. Kolyvanova, Maria E. Kartseva, Elena M. Shishmakova, Olga V. Dement’eva, Alexandra K. Isagulieva, Magomet H. Salpagarov, Alexandr V. Belousov, Victor M. Rudoy, Alexander A. Shtil, Alexander S. Samoylov & Vladimir N. Morozov. (2020) Radiosensitization by Gold Nanoparticles: Impact of the Size, Dose Rate, and Photon Energy. Nanomaterials 10:5, pages 952.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.